Literature DB >> 11460890

Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

F Brambilla1.   

Abstract

Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biological bases have been proposed repeatedly, based on several lines of evidence: hunger, satiety and food choice are regulated by neurotransmitters and neuropeptides, and impairment of eating habits may be related to alterations in the secretion of these chemicals; genetic studies suggest that these neurotransmitter systems are dysfunctional in individuals with bulimia nervosa; and the frequent comorbidity of bulimia nervosa with major depressive and obsessive-compulsive disorders, conditions in which multiple alterations of brain biochemical functions have been demonstrated. Data in the literature suggest that levels of noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) are lower in individuals with bulimia nervosa than in healthy controls. Levels of dopamine are similar to, or lower than, those in controls. After remission of the disorder, noradrenergic function returns to that seen in controls, whereas dopaminergic and serotonergic function rebound to levels higher than in controls. Among the neuropeptides, alterations in the levels of neuropeptide Y, peptide YY, beta-endorphin, corticotrophin-releasing hormone, somatostatin, cholecystokinin and vasopressin have been found in the symptomatic phase of bulimia nervosa, with a return to levels seen in controls after remission. Pharmacological treatment of bulimia nervosa that is directed at correction of the neurochemical alterations observed is difficult because of the complexity of the impairments. However, such treatment is necessary and should be continued long after symptomatic remission to ensure reinstitution of cerebral biochemical homeostasis.

Entities:  

Mesh:

Year:  2001        PMID: 11460890     DOI: 10.2165/00023210-200115020-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  113 in total

Review 1.  Leptin and the neuroendocrinology of fasting.

Authors:  R S Ahima
Journal:  Front Horm Res       Date:  2000       Impact factor: 2.606

2.  Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats.

Authors:  J J Wurtman; R J Wurtman
Journal:  Life Sci       Date:  1979-03-05       Impact factor: 5.037

3.  Peripheral opioid secretory pattern in anorexia nervosa.

Authors:  F Brambilla; E Ferrari; F Petraglia; F Facchinetti; M Catalano; A R Genazzani
Journal:  Psychiatry Res       Date:  1991-11       Impact factor: 3.222

4.  Metabolic and endocrine indices of starvation in bulimia: a comparison with anorexia nervosa.

Authors:  K M Pirke; J Pahl; U Schweiger; M Warnhoff
Journal:  Psychiatry Res       Date:  1985-05       Impact factor: 3.222

5.  Low leptin levels predict amenorrhea in underweight and eating disordered females.

Authors:  W Köpp; W F Blum; S von Prittwitz; A Ziegler; H Lübbert; G Emons; W Herzog; S Herpertz; H C Deter; H Remschmidt; J Hebebrand
Journal:  Mol Psychiatry       Date:  1997-07       Impact factor: 15.992

6.  Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.

Authors:  R C Veith; N Lewis; J I Langohr; M M Murburg; E A Ashleigh; S Castillo; E R Peskind; M Pascualy; G Bissette; C B Nemeroff
Journal:  Psychiatry Res       Date:  1993-01       Impact factor: 3.222

7.  Effect of adrenalectomy and glucocorticoid replacement on development of obesity.

Authors:  M R Freedman; B A Horwitz; J S Stern
Journal:  Am J Physiol       Date:  1986-04

8.  Lymphocyte cholecystokinin concentrations in panic disorder.

Authors:  F Brambilla; L Bellodi; G Perna; A Garberi; A Panerai; P Sacerdote
Journal:  Am J Psychiatry       Date:  1993-07       Impact factor: 18.112

9.  Satiety and cholecystokinin.

Authors:  K M Pirke; M B Kellner; E Friess; J C Krieg; M M Fichter
Journal:  Int J Eat Disord       Date:  1994-01       Impact factor: 4.861

10.  Hyperprolactinemia stimulates food intake in the female rat.

Authors:  B J Moore; T Gerardo-Gettens; B A Horwitz; J S Stern
Journal:  Brain Res Bull       Date:  1986-10       Impact factor: 4.077

View more
  5 in total

Review 1.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

2.  The pharmacological options in the treatment of eating disorders.

Authors:  W Milano; M De Rosa; L Milano; A Riccio; B Sanseverino; A Capasso
Journal:  ISRN Pharmacol       Date:  2013-07-15

Review 3.  Effects of Microbiota Imbalance in Anxiety and Eating Disorders: Probiotics as Novel Therapeutic Approaches.

Authors:  Elisabet Navarro-Tapia; Laura Almeida-Toledano; Giorgia Sebastiani; Mariona Serra-Delgado; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

4.  Effects of milnacipran on binge eating - a pilot study.

Authors:  Shun'ichi Noma; Teruhisa Uwatoko; Haruka Yamamoto; Takuji Hayashi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

Review 5.  The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa.

Authors:  Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova
Journal:  Int J Endocrinol       Date:  2013-09-09       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.